OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

NCT04454788 · University of Melbourne · PHASE3 · terminated · last registry update 2025-01-15 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Loss of equipoise in the 0-4.5h population which comprised the majority of ETERNAL-LVO trial recruitment due to publication of other trials demonstrating efficacy of tenecteplase vs alteplase in the 0-4.5h time window.”–Registry record, University of Melbourne

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision